MarketCap
Facebook
X
TelegramAnnual report 2024
added 02-28-2026
argenx SE General and Administrative Expenses 2011-2026 | ARGX
General and Administrative Expenses — these are a part of a company's operating expenses that are not directly related to the production of goods or the provision of services but are necessary for the overall functioning of the business.What these expenses include
- Salaries of administrative staff (executives, HR, accountants, legal personnel)
- Office rent and utilities
- Office equipment and IT infrastructure
- Professional services (auditors, lawyers, consultants)
- Insurance
- General administrative travel and representation expenses
- Cost control
A high level of such expenses may indicate inefficient management or an overly complex structure - Profitability
Reducing administrative expenses while maintaining stable revenue increases operating profit - Comparative analysis
Investors can compare this metric as a percentage of revenue among companies in the same industry - Business flexibility
Companies with a flexible and controlled expense structure are more resilient to revenue declines
Annual General and Administrative Expenses argenx SE
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | - | 308 M | 149 M | 53.8 M | 27.5 M | 12.4 M | 7.01 M | 4.92 M | 3.21 M | 1.59 M | 1.66 M | 1.46 M |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 308 M | 1.46 M | 51.9 M |
General and Administrative Expenses of other stocks in the Biotechnology industry
| Issuer | General and Administrative Expenses | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
MorphoSys AG
MOR
|
78.3 M | - | 2.43 % | $ 254 M |  Germany |
 |
Acer Therapeutics
ACER
|
12.7 M | - | 2.71 % | $ 14 M |  USA |
 |
Acorda Therapeutics
ACOR
|
89.7 M | - | -24.86 % | $ 820 K | USA |
 |
AgeX Therapeutics
AGE
|
9.33 M | - | -10.17 % | $ 12.2 K | USA |
 |
Aeglea BioTherapeutics
AGLE
|
47.9 M | - | - | $ 1.01 B | USA |
 |
Applied Genetic Technologies Corporation
AGTC
|
17 M | - | - | $ 26.5 M | USA |
 |
AbCellera Biologics
ABCL
|
83.2 M | $ 3.59 | -1.24 % | $ 1.07 B |  Canada |
 |
I-Mab
IMAB
|
900 M | - | - | $ 866 M |  China |
 |
ADMA Biologics
ADMA
|
91.6 M | $ 15.71 | -5.02 % | $ 3.74 B | USA |
 |
Alexion Pharmaceuticals, Inc.
ALXN
|
1.4 B | - | - | $ 40.3 B | USA |
 |
Biophytis SA
BPTS
|
7.15 M | - | -13.47 % | $ 169 M |  France |
 |
Aptorum Group Limited
APM
|
5.41 M | $ 0.82 | -0.73 % | $ 4.47 M | China |
 |
EyeGate Pharmaceuticals, Inc.
EYEG
|
4.66 M | - | -1.52 % | $ 24.7 M | USA |
 |
Midatech Pharma plc
MTP
|
4.95 M | - | -18.52 % | $ 27.3 M |  Britain |
 |
Akero Therapeutics
AKRO
|
37.9 M | - | - | $ 3.67 B | USA |
 |
Akouos
AKUS
|
22.2 M | - | 0.23 % | $ 488 M | USA |
 |
Alpine Immune Sciences
ALPN
|
18 M | - | - | $ 2.17 B | USA |
 |
AlloVir
ALVR
|
42.9 M | - | 4.14 % | $ 49.1 M | USA |
 |
Apellis Pharmaceuticals
APLS
|
550 M | $ 20.29 | 2.17 % | $ 2.56 B | USA |
 |
Ampio Pharmaceuticals
AMPE
|
7.08 M | - | -11.43 % | $ 502 K | USA |
 |
ANI Pharmaceuticals
ANIP
|
250 M | $ 75.95 | -0.76 % | $ 1.47 B | USA |
 |
Applied Therapeutics
APLT
|
20.6 M | - | - | $ 8.42 M | USA |
 |
Autolus Therapeutics plc
AUTL
|
46.7 M | $ 1.5 | -7.98 % | $ 383 M | Britain |
 |
Aravive
ARAV
|
13 M | - | -13.39 % | $ 1.45 M | USA |
 |
Adverum Biotechnologies
ADVM
|
63.1 M | - | - | $ 86.2 M | USA |
 |
Институт стволовых клеток человека
ISKJ
|
25.8 M | - | - | - |  Russia |
 |
Athersys
ATHX
|
20.1 M | - | 3.77 % | $ 22.4 M | USA |
 |
ARCA biopharma
ABIO
|
13.1 M | - | 1052.0 % | $ 415 M | USA |
 |
Corcept Therapeutics Incorporated
CORT
|
449 M | $ 34.35 | -3.74 % | $ 3.57 B | USA |
 |
AVEO Pharmaceuticals
AVEO
|
60.8 M | - | - | $ 521 M | USA |
 |
Corbus Pharmaceuticals Holdings
CRBP
|
13.9 M | $ 7.99 | -5.17 % | $ 34.6 M | USA |
 |
CorMedix
CRMD
|
35.8 M | $ 6.35 | -10.88 % | $ 323 M | USA |
 |
Champions Oncology
CSBR
|
9.34 M | $ 5.79 | -3.58 % | $ 79.1 M | USA |
 |
Axsome Therapeutics
AXSM
|
63.3 M | $ 160.64 | -2.1 % | $ 7.99 B | USA |
 |
BridgeBio Pharma
BBIO
|
531 M | $ 65.51 | -1.55 % | $ 12.5 B | USA |
 |
Brainstorm Cell Therapeutics
BCLI
|
7.04 M | - | -2.5 % | $ 5.88 M | USA |
 |
BioDelivery Sciences International
BDSI
|
106 M | - | -4.8 % | $ 255 M | USA |
 |
Denali Therapeutics
DNLI
|
105 M | $ 19.73 | -3.17 % | $ 3.25 B | USA |
 |
Acasti Pharma
ACST
|
7.17 M | - | 4.01 % | $ 150 M | Canada |
 |
BeiGene, Ltd.
BGNE
|
2.08 B | - | 0.49 % | $ 251 B |  Cayman-islands |
 |
Edesa Biotech
EDSA
|
4.13 M | $ 3.71 | -13.11 % | $ 11.9 M | USA |
 |
Bellicum Pharmaceuticals
BLCM
|
5.72 M | - | -9.72 % | $ 5.89 M | USA |
 |
Berkeley Lights
BLI
|
95.1 M | - | -7.31 % | $ 87 M | USA |
 |
Equillium
EQ
|
13.6 M | $ 1.79 | 2.29 % | $ 62.2 M | USA |
 |
CureVac N.V.
CVAC
|
100 M | - | - | $ 867 M | Germany |
 |
Aeterna Zentaris
AEZS
|
5.92 M | - | 5.93 % | $ 314 M | Canada |
 |
Bellerophon Therapeutics
BLPH
|
6.02 M | - | -74.18 % | $ 955 K | USA |
 |
BioLineRx Ltd.
BLRX
|
4.31 M | $ 2.75 | -1.96 % | $ 908 M |  Israel |
 |
BioMarin Pharmaceutical
BMRN
|
1.15 B | $ 60.6 | 0.28 % | $ 11.6 B | USA |
 |
Burford Capital Limited
BUR
|
99.3 M | $ 8.26 | -1.31 % | $ 1.36 B | Britain |